Boston Trust Walden Corp Raises Stock Position in Stryker Co. (NYSE:SYK)

Boston Trust Walden Corp boosted its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 443,458 shares of the medical technology company's stock after acquiring an additional 11,021 shares during the period. Stryker accounts for about 1.0% of Boston Trust Walden Corp's holdings, making the stock its 18th biggest position. Boston Trust Walden Corp owned 0.12% of Stryker worth $132,798,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of SYK. Norges Bank purchased a new position in Stryker in the 4th quarter worth approximately $776,333,000. Moneta Group Investment Advisors LLC grew its stake in Stryker by 109,726.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 3,139,948 shares of the medical technology company's stock worth $767,686,000 after buying an additional 3,137,089 shares in the last quarter. Ontario Teachers Pension Plan Board grew its stake in Stryker by 87,902.2% in the 1st quarter. Ontario Teachers Pension Plan Board now owns 2,077,732 shares of the medical technology company's stock worth $555,482,000 after buying an additional 2,075,371 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in Stryker in the 4th quarter worth approximately $312,539,000. Finally, Morgan Stanley grew its stake in Stryker by 21.7% in the 4th quarter. Morgan Stanley now owns 5,978,782 shares of the medical technology company's stock worth $1,461,753,000 after buying an additional 1,066,751 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Stock Down 1.0 %

Shares of NYSE:SYK traded down $3.57 during midday trading on Thursday, reaching $347.43. The company's stock had a trading volume of 888,860 shares, compared to its average volume of 1,297,323. The firm has a 50 day moving average of $347.58 and a 200-day moving average of $307.64. The firm has a market capitalization of $132.19 billion, a P/E ratio of 42.70, a PEG ratio of 2.85 and a beta of 0.89. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping analysts' consensus estimates of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the firm earned $3.00 EPS. The company's revenue was up 11.8% compared to the same quarter last year. On average, research analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker's dividend payout ratio is currently 38.79%.

Analyst Ratings Changes

SYK has been the subject of a number of research reports. Canaccord Genuity Group raised shares of Stryker from a "hold" rating to a "buy" rating and boosted their price target for the stock from $315.00 to $360.00 in a research note on Wednesday, January 31st. Royal Bank of Canada restated an "outperform" rating and issued a $360.00 price objective on shares of Stryker in a report on Thursday, February 15th. Truist Financial boosted their price objective on shares of Stryker from $330.00 to $345.00 and gave the stock a "hold" rating in a report on Wednesday, January 31st. Roth Mkm boosted their price objective on shares of Stryker from $345.00 to $348.00 and gave the stock a "buy" rating in a report on Wednesday, January 31st. Finally, Citigroup boosted their price objective on shares of Stryker from $362.00 to $406.00 and gave the stock a "buy" rating in a report on Wednesday. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $335.27.

Insider Buying and Selling at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company's stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 212,109 shares of company stock worth $72,845,768. Company insiders own 5.90% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.